Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell tags : Trial save search
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
VIRX | $0.8971 -4.18% -4.36% 79K
|
Manufacturing
|
| O: -12.71%
H: 0.97%
C: -24.27%
t-cell positive topline trial therapeutics results
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
|
| O: -100.0%
H: NaN%
C: Infinity%
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.5%
H: 0.83%
C: 0.28%
CTXR | $0.8 -1.99% -2.02% 6.3M
|
Health Technology
|
| O: 2.33%
H: 2.28%
C: -4.23%
hope treatment pharmaceuticals city for car-t trial
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
Published: 2024-03-07 (Crawled : 12:30) - globenewswire.com
MBIO | $0.3819 -0.55% -1.05% 200K
|
Health Technology
|
| O: 8.33%
H: 4.2%
C: -2.8%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 2.93%
H: 0.0%
C: -9.21%
mb-101 publication trial
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
Published: 2024-03-07 (Crawled : 12:30) - biospace.com/
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
|
| O: 0.79%
H: 0.78%
C: 0.78%
MBIO | $0.3819 -0.55% -1.05% 200K
|
Health Technology
|
| O: 8.33%
H: 4.2%
C: -2.8%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 2.93%
H: 0.0%
C: -9.21%
tumors cell city trial therapy
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
Published: 2024-02-29 (Crawled : 13:00) - globenewswire.com
VIRX | $0.8971 -4.18% -4.36% 79K
|
Manufacturing
|
| O: 0.0%
H: 3.37%
C: -8.43%
t-cell trial therapeutics
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell LymphomaCompany on track to initiate soquelitinib Phase 3 registrational clinical trial in PTCL
Published: 2024-02-08 (Crawled : 23:00) - biospace.com/
CRVS | $1.43 5.15% 4.9% 140K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -3.38%
drug granted cell treatment pharmaceuticals designation trial
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
Published: 2024-01-04 (Crawled : 21:00) - globenewswire.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: -17.4%
H: 4.64%
C: 4.11%
first trial therapeutics platform
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
Published: 2023-12-09 (Crawled : 20:20) - globenewswire.com
CRVS | $1.43 5.15% 4.9% 140K
|
Health Technology
| Email alert
Add to watchlist
cell pharmaceuticals trial
Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition
Published: 2023-11-02 (Crawled : 13:00) - globenewswire.com
CRVS | $1.43 5.15% 4.9% 140K
|
Health Technology
|
| O: 5.93%
H: 5.59%
C: -2.4%
cell pharmaceuticals meeting trial
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
Published: 2023-10-23 (Crawled : 18:00) - biospace.com/
ADAP | $0.8984 -8.98% -9.86% 3.3M
|
Health Technology
|
| O: 6.19%
H: 3.33%
C: 0.05%
t-cell update trial therapy
Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
Published: 2023-10-21 (Crawled : 16:20) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
| Email alert
Add to watchlist
hpn328 congress cell trial therapeutics response
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma
Published: 2023-10-12 (Crawled : 12:00) - globenewswire.com
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: 1.0%
H: 0.0%
C: -5.94%
inb-100 inb-400 cell treatment trial potential therapy glioblastoma
SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas
Published: 2023-10-11 (Crawled : 13:00) - globenewswire.com
SLS | $1.505 6.74% 6.31% 1.6M
|
Health Technology
|
| O: -0.7%
H: 7.8%
C: -14.89%
sls009 t-cell lymphomas trial
GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)
Published: 2023-10-10 (Crawled : 12:30) - biospace.com/
SLS | $1.505 6.74% 6.31% 1.6M
|
Health Technology
|
| O: 0.0%
H: 10.48%
C: -0.7%
gfh009 t-cell lymphomas trial
Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
Published: 2023-10-09 (Crawled : 20:00) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
|
| O: -2.12%
H: 11.81%
C: 1.86%
hpn328 congress cell trial therapeutics response
Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
Published: 2023-09-06 (Crawled : 20:00) - globenewswire.com
CRVS | $1.43 5.15% 4.9% 140K
|
Health Technology
|
| O: 2.39%
H: 6.07%
C: -23.36%
cpi-818 fda cell pharmaceuticals meeting trial
Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy
Published: 2023-08-16 (Crawled : 12:00) - globenewswire.com
MBIO | $0.3819 -0.55% -1.05% 200K
|
Health Technology
|
| O: 5.53%
H: 0.0%
C: -9.23%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 1372.45%
H: 1.87%
C: -3.85%
mb-106 cell ongoing car-t trial therapy
HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment
Published: 2023-08-10 (Crawled : 13:00) - biospace.com/
SNGX | $0.42 -17.65% -21.43% 6.3M
|
Health Technology
|
| O: 0.02%
H: 0.37%
C: -2.78%
t-cell treatment trial
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Published: 2023-08-09 (Crawled : 11:00) - globenewswire.com
CGEM | $18.06 1.01% 1.0% 700K
|
|
| O: 4.0%
H: 0.0%
C: 0.0%
cln-978 cell trial
Viracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)
Published: 2023-06-28 (Crawled : 12:00) - globenewswire.com
VIRX | $0.8971 -4.18% -4.36% 79K
|
Manufacturing
|
| O: 1.4%
H: 8.91%
C: 4.14%
t-cell expansion trial
Gainers vs Losers
| 66% | 34% |
Top 10 Gainers
AGBA | $1.02 155.0% 60.78% 120M
|
Finance
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 900K
|
OST | $0.499 21.38% 45.26% 1.9M
|
ZCMD | $2.44 78.1% 43.85% 330K
|
Commercial Services
XPON | $3.1 60.62% 37.74% 16M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.